Posterior epistaxis accounts for 10–20% of all epistaxis cases, arising from branches of the sphenopalatine and ascending pharyngeal arteries. It is more profuse, harder to control, and carries a greater risk of airway compromise and aspiration than anterior epistaxis. [1] The following figure illustrates the dual blood supply (internal and external carotid systems) and the posterior vascular anatomy relevant to this condition.
1. History
- Onset, duration, laterality, and estimated volume of blood loss
- Bleeding from both nares or into the oropharynx (classic for posterior source)
- Prior episodes, frequency, and prior interventions (cautery, packing)
- History of nasal/facial trauma or recent nasal surgery
- Anticoagulant/antiplatelet use — type, dose, timing of last dose [1][3]
- Coexisting conditions: hypertension, liver disease, renal disease, bleeding disorders, HHT
- Intranasal medication use (nasal steroids, decongestants, cocaine)
- Family history of bleeding disorders or HHT
- Important negatives: no weight loss, no unilateral obstruction, no facial pain (helps exclude mass)
2. Alarm Features
- Hemodynamic instability: tachycardia, hypotension, syncope, pallor, diaphoresis [1]
- Bilateral nasal bleeding or blood draining from the oropharynx
- Airway compromise or aspiration risk (especially in obtunded patients) [1]
- Massive blood loss (>250 mL) or need for transfusion
- Recurrent unilateral epistaxis with nasal obstruction → concern for nasal/nasopharyngeal mass (angiofibroma in adolescent males, malignancy in older adults) [3]
- Supratherapeutic INR (>4.5) — associated with higher admission rates and prolonged stays [3]
- Signs of coagulopathy: bleeding from multiple sites, extensive bruising
3. Medications
Contributing medications
- Anticoagulants: warfarin, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), heparin/LMWH
- Antiplatelets: aspirin, clopidogrel, prasugrel, ticagrelor
- Intranasal corticosteroids (mucosal drying/friability)
- NSAIDs (platelet dysfunction)
- Herbal supplements: ginkgo, garlic, fish oil
Acute treatment medications
- Topical vasoconstrictors: oxymetazoline (0.05%) — avoid in patients with significant cardiovascular disease [1]
- Topical anesthetics: lidocaine 4% or tetracaine on pledgets [3]
- Topical tranexamic acid (TXA): soaked pledgets; oral TXA also effective [3-4]
- Desmopressin: useful adjunct for platelet dysfunction or uremia [3]
Anticoagulant management
- Withhold next dose during active bleeding; do NOT reflexively reverse anticoagulation [3]
- Reversal only for life-threatening bleeding, in consultation with appropriate specialist
- Reversal agents per medication class are summarized in the following figure:
4. Diet
- Avoid hot foods/beverages for 24–48 hours after bleeding controlled (may promote vasodilation)
- Avoid alcohol (vasodilatory, impairs platelet function)
- Adequate hydration to maintain mucosal moisture
- Long-term: humidification of inspired air, especially in dry/cold climates
5. Review of Systems
- HEENT: unilateral obstruction, facial pain/pressure, anosmia (mass lesion), oral bleeding
- Hematologic: easy bruising, gingival bleeding, heavy menses, prolonged bleeding from cuts
- Cardiovascular: chest pain, dyspnea, palpitations (assess hemodynamic impact)
- GI: hematemesis, melena (swallowed blood)
- Dermatologic: telangiectasias on lips, tongue, fingertips (HHT) [1]
- Constitutional: weight loss, fatigue (malignancy, anemia)
6. Collateral History and Family History
- Family history of hereditary hemorrhagic telangiectasia (autosomal dominant; prevalence ~1:5000) — recurrent epistaxis is the hallmark presentation [1]
- Family history of bleeding disorders: von Willebrand disease (up to 5–10% of children with recurrent epistaxis), hemophilia [6]
- Collateral from family/EMS: estimated blood loss, duration, witnessed syncope
- Social history: cocaine use (potent vasoconstrictor causing rebound mucosal damage), tobacco use
7. Risk Factors
- Age >60 years — posterior epistaxis is more common in older adults [3-4]
- Hypertension — most commonly detected comorbidity (39% of epistaxis presentations) [3][7]
- Anticoagulant/antiplatelet therapy — 15% of epistaxis patients on long-term anticoagulation [3]
- Atherosclerosis and cardiovascular disease [1]
- Coagulopathies: liver disease, renal failure, hematologic malignancy [8]
- HHT [8]
- Dry environment / low humidity / cold climate [6]
- Prior nasal surgery or trauma
- Intranasal drug use (cocaine, nasal steroids)
8. Differential Diagnosis
- Anterior epistaxis (most common mimic — 80–90% of all epistaxis) [1]
- Nasal/nasopharyngeal mass: juvenile nasopharyngeal angiofibroma (adolescent males), squamous cell carcinoma, lymphoma [3]
- Coagulopathy: von Willebrand disease, hemophilia, DIC, thrombocytopenia, liver failure
- HHT (Osler-Weber-Rendu syndrome) [1]
- Facial/skull base fracture with secondary hemorrhage [9]
- Foreign body (especially in children) [3]
- Hemoptysis or hematemesis misidentified as epistaxis
- Carotid artery pseudoaneurysm (rare, post-surgical or post-traumatic — massive, life-threatening)
9. Past Medical History
- Prior epistaxis episodes and interventions (cautery, packing, surgery, embolization)
- Hypertension, cardiovascular disease, heart failure
- Liver disease (coagulopathy, thrombocytopenia)
- Renal disease (uremic platelet dysfunction)
- Bleeding disorders or hematologic malignancy
- Prior nasal/sinus surgery
- History of HHT or AVM
10. Physical Exam
Vital signs
Focused exam
- Anterior rhinoscopy with nasal speculum and headlight after clot removal — mandatory first step [1][3]
- Assess for active bleeding source; if no anterior source identified → suspect posterior origin
- Oropharyngeal exam: blood draining down posterior pharynx confirms posterior source
- Skin: telangiectasias (lips, tongue, fingertips → HHT), petechiae, ecchymoses
- Nasal endoscopy (rigid or flexible) — recommended for persistent/recurrent bleeding or when anterior source not identified; localizes bleeding site in 87–93% of cases [3]
- Posterior epistaxis sites: posterior septum (70%), lateral nasal wall (24%), nasal floor (8%) [1]
11. Lab Studies
- CBC: hemoglobin/hematocrit (assess blood loss severity), platelet count
- Coagulation studies: PT/INR (especially if on warfarin), PTT (if on heparin) [3][10]
- Type and screen/crossmatch: if significant hemorrhage or anticipated transfusion
- BMP: renal function (uremic platelet dysfunction)
- Liver function tests: if liver disease suspected
- Coagulation screening is most useful in patients on anticoagulants or with suspected bleeding diathesis [10]
12. Imaging
- Not routinely indicated for acute epistaxis [11]
- CT angiography: preferred for vascular assessment and interventional planning in severe, recurrent, or posterior bleeding [11]
- CT paranasal sinuses: indicated if concern for mass, recurrent unilateral epistaxis, or inflammatory disease [11-12]
- MRI: when soft tissue or intracranial extension of a mass is suspected [11]
- Angiography: performed at time of embolization if endovascular intervention planned
13. Special Tests
- Nasal endoscopy — the key diagnostic procedure; localizes posterior bleeding source and guides treatment [3]
- Point-of-care hemoglobin (iSTAT or similar) for rapid assessment
- Thromboelastography (TEG) or ROTEM: may be useful in complex coagulopathy
- Consider von Willebrand panel and platelet function assays in recurrent epistaxis without clear cause, especially in younger patients [6]
- Epistaxis Severity Score (ESS): validated tool for HHT-related epistaxis to track severity over time [13]
14. ECG
- Obtain ECG if:
- Significant blood loss with tachycardia or hemodynamic instability
- Elderly patients or those with known cardiovascular disease
- Pre-procedural assessment if surgical intervention anticipated
- Look for: sinus tachycardia, ST changes suggesting demand ischemia, atrial fibrillation (relevant to anticoagulation decisions)
15. Assessment
Posterior epistaxis is a clinical diagnosis made when no anterior bleeding source is identified on rhinoscopy and blood is seen draining into the posterior pharynx. [1][3] It is more common in older adults with hypertension and atherosclerosis. [4] Key distinguishing features from anterior epistaxis:
- Bleeding from both nares or predominantly into the oropharynx
- Failure to control with anterior pressure/packing
- More profuse hemorrhage with greater risk of hemodynamic compromise
- Higher rates of rebleeding (up to 52% with posterior packing alone) [3]
Severity stratification should incorporate volume of blood loss, hemodynamic status, comorbidities, and anticoagulation status. Complications include aspiration, airway obstruction, anemia requiring transfusion, and complications of packing (otitis media, sinusitis, tissue necrosis, toxic shock syndrome). [1]
16. Treatment Plan
Initial stabilization
- ABCs — assess airway and hemodynamic status; IV access, fluid resuscitation if needed [1]
- Digital compression of the lower third of the nose for 15–20 minutes [1][9]
- Sit upright, lean forward, spit out blood
Stepwise escalation
- Topical vasoconstrictors (oxymetazoline on pledgets) + topical anesthetic (lidocaine 4%) — caution in cardiovascular disease [1][3]
- Topical TXA on pledgets — effective adjunct [3-4]
- Anterior rhinoscopy → if bleeding source identified, electrocautery (preferred over chemical cautery) [3]
- If no source identified or bleeding persists → nasal endoscopy [3]
- Posterior packing: double-balloon catheter (e.g., Rapid Rhino posterior) or Foley catheter (10–14 Fr, inflate balloon with 7–15 mL saline) + anterior packing [1][3]
- Double-balloon catheters control ~70% of posterior epistaxis [3]
- Posterior packing is very uncomfortable and carries significant complications [1]
- Endoscopic sphenopalatine artery (SPA) ligation — increasingly used as second-line (rather than third-line) therapy; success rate >90% [3][14]
- Endovascular embolization — alternative to surgical ligation; success >90%; typically reserved for surgical failures or patients who are poor surgical candidates [3]
Anticoagulation management
- Initiate first-line local treatments before considering reversal [3]
- Withhold next anticoagulant/antiplatelet dose during active bleeding [1]
- Reversal only for life-threatening hemorrhage, in consultation with hematology/cardiology [3]
17. Disposition
Admission criteria
- All patients with posterior packing require admission — risk of airway obstruction, hypoxemia (nasopulmonary reflex), and need for monitoring [1]
- Hemodynamic instability or significant blood loss requiring transfusion
- Supratherapeutic INR (>4.5) [3]
- Failed initial management requiring ENT consultation for surgical intervention
- Significant comorbidities (cardiovascular disease, coagulopathy) with ongoing bleeding risk
Observation indications
- Controlled anterior bleeding in anticoagulated patients
- Borderline hemoglobin after significant hemorrhage
Discharge criteria
- Bleeding controlled with anterior measures only (no posterior packing)
- Hemodynamically stable, adequate hemoglobin
- Reliable patient with ability to return
Specialist consultation triggers
- ENT (urgent): all posterior epistaxis, failed anterior packing/cautery, recurrent unilateral bleeding, suspected mass [3]
- Interventional radiology: refractory bleeding for embolization consideration [3]
- Hematology: suspected coagulopathy, need for anticoagulation reversal guidance
18. Follow Up / Return Precautions
Follow-up timing
- ENT follow-up within 24–48 hours if posterior packing placed (for pack removal and reassessment)
- Nonresorbable anterior packing: removal in 24–72 hours
- Resorbable packing: no removal needed; follow-up in 1–2 weeks
- PCP follow-up within 1 week for blood pressure optimization and medication review
Return precautions — instruct patients to return immediately for:
- Recurrent brisk bleeding not controlled by 20 minutes of firm pressure
- Difficulty breathing or swallowing
- Lightheadedness, syncope, or palpitations
- Hematemesis or large-volume blood expectoration
- Fever (concern for toxic shock syndrome or sinusitis with packing in place)
Patient counseling
- Avoid nose blowing, straining, heavy lifting, and hot beverages for 1–2 weeks
- Use saline nasal spray and nasal moisturizer (petroleum jelly) to prevent mucosal drying [13]
- Humidify home environment
- Avoid aspirin/NSAIDs unless medically necessary
- Expected recovery: most episodes resolve with treatment, but rebleeding risk is higher with posterior sources [4]
References
1. Epistaxis. — Seikaly H. The New England Journal of Medicine. 2021.
2. Epistaxis. — Schlosser RJ. The New England Journal of Medicine. 2009.
3. Clinical Practice Guideline: Nosebleed (Epistaxis). — Tunkel DE, Anne S, Payne SC, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2020.
4. Tranexamic Acid for Patients With Nasal Haemorrhage (Epistaxis). — Joseph J, Martinez-Devesa P, Bellorini J, Burton MJ. The Cochrane Database of Systematic Reviews. 2018.
5. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. — Tomaselli GF, Mahaffey KW, Cuker A, et al. Journal of the American College of Cardiology. 2017.
6. Interventions for Recurrent Idiopathic Epistaxis (Nosebleeds) in Children. — Qureishi A, Burton MJ. The Cochrane Database of Systematic Reviews. 2012.
7. Overview of Etiology and Management of Epistaxis: Through the Mnemonic EPISTAXIS. — Özbay S, Bayar Muluk N, Yagci T, et al. The Journal of Craniofacial Surgery. 2025.
8. Risk Factors and Management Outcomes in Epistaxis: A Tertiary Centre Experience. — Hughes JM, Teh BM, Hart CJ, Gibbs HH, Aung AK. ANZ Journal of Surgery. 2023.
9. 2024 American Heart Association and American Red Cross Guidelines for First Aid. — Hewett Brumberg EK, Douma MJ, Alibertis K, et al. Circulation. 2024.
10. Initial Assessment in the Management of Adult Epistaxis: Systematic Review. — Khan M, Conroy K, Ubayasiri K, et al. The Journal of Laryngology and Otology. 2017.
11. ESR Essentials: Imaging in Nasal Obstruction and Epistaxis-Practice Recommendations by the European Society of Head and Neck Radiology. — Péporté ARJ, Vassallo E, Preda L, Beale T, Hirvonen J. European Radiology. 2026.
12. Computed Tomography Findings in Patients With Primarily Unknown Causes of Severe or Recurrent Epistaxis. — van Horn N, Faizy TD, Schoenfeld MH, et al. PloS One. 2019.
13. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. — Faughnan ME, Mager JJ, Hetts SW, et al. Annals of Internal Medicine. 2020.
14. Posterior Epistaxis Management: Review of the Literature and Proposed Guidelines of the Hellenic Rhinological-Facial Plastic Surgery Society. — Koskinas I, Terzis T, Georgalas C, et al. European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies : Affiliated With the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2024.